 Rifampin
"Rifampin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
| Descriptor ID |
D012293
|
| MeSH Number(s) |
D03.633.400.811.700 D04.345.295.750.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Rifampin".
Below are MeSH descriptors whose meaning is more specific than "Rifampin".
This graph shows the total number of publications written about "Rifampin" by people in this website by year, and whether "Rifampin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 2 | 0 | 2 | | 2002 | 1 | 0 | 1 | | 2003 | 1 | 1 | 2 | | 2004 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 | | 2008 | 0 | 2 | 2 | | 2009 | 0 | 1 | 1 | | 2010 | 0 | 4 | 4 | | 2011 | 0 | 2 | 2 | | 2012 | 0 | 4 | 4 | | 2013 | 1 | 1 | 2 | | 2014 | 0 | 2 | 2 | | 2015 | 0 | 1 | 1 | | 2016 | 1 | 3 | 4 | | 2017 | 2 | 1 | 3 | | 2018 | 3 | 1 | 4 | | 2019 | 1 | 2 | 3 | | 2020 | 1 | 3 | 4 | | 2021 | 2 | 3 | 5 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 5 | 5 | | 2024 | 1 | 1 | 2 | | 2025 | 1 | 3 | 4 | | 2026 | 1 | 3 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Rifampin" by people in Profiles.
-
Hendrix J, Al Mubarak R, Reichlen MJ, Tabor ST, Bateman A, Massoudi LM, Rossmassler K, Kaya F, Zimmerman MD, Nielsen H, Wynn EA, Voskuil MI, Robertson GT, Moore CM, Walter ND. Physiologic recovery of Mycobacterium tuberculosis from drug injury: A molecular study of post antibiotic effect in vitro and in vivo. PLoS Pathog. 2026 Apr; 22(4):e1014131.
-
Mpofu R, Chandiwana N, Sokhela S, Moorhouse M, Venter F, Anderson PL, Wiesner L, Boffito M, Maartens G, Sinxadi P. The Effect of Rifampicin on the Plasma and Intracellular Pharmacokinetics of Tenofovir Alafenamide Fumarate in HIV-associated Tuberculosis. J Acquir Immune Defic Syndr. 2026 Apr 01; 101(4):424-431.
-
Hughes JA, McMorrow F, Brooks KM, Pinilla M, Fairlie L, Ngocho JS, Stek A, Best BM, Mirochnick M, Wiesner L, George K, Knowles K, Browning R, DeYampert T, Hesseling AC, Decloedt E, Shapiro DE, Eke AC. Pharmacokinetics and Safety of Clofazimine in Women With Rifampicin-resistant Tuberculosis During Pregnancy and the Postpartum Period: Results From IMPAACT P1026s. J Infect Dis. 2026 Jan 17; 233(1):16-26.
-
Sordello S, Brock L, Tagliavini A, Federico D, Boulenc X, Pergher M, Huc Claustre E, Metcalf D, Walter ND, Robertson GT, Clary J, Berg A, Mdluli K, Hermann D, Flood D, Upton AM. A modeling-based framework to evaluate forgiveness of tuberculosis treatment in a BALB/c relapsing mouse model. Antimicrob Agents Chemother. 2026 Feb 04; 70(2):e0110925.
-
Kurbatova EV, Dooley KE, Carr W, Stout JE, Nuermberger EL, Phillips PPJ, Scott NA, Upton CM, Ignatius E, Haas M, Walter ND, Traxler RM, Brown NE, Boyd R, Bryant KE, Dixon MG, Savic R, Eichberg C, Hesseling A, Bark C, Benator DA, Muzanyi G, Twycross NS, Fox GJ, Pierre S, Burzynski J, Fitzgerald DW. Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB design. Contemp Clin Trials. 2025 Nov; 158:108075.
-
Hughes JA, Pinilla M, Brooks KM, Eke AC, Stek A, Best BM, Mirochnick M, Browning R, Wiesner L, George K, Knowles K, De Koker P, Ngocho JS, Fairlie L, Chakhtoura N, Hesseling AC, Decloedt E, Shapiro DE, van Schalkwyk M. Pharmacokinetics and Safety of Levofloxacin for Treatment of Rifampicin-Resistant Tuberculosis During Pregnancy and the Postpartum Period: Results from IMPAACT P1026s. Clin Pharmacokinet. 2025 Apr; 64(4):619-630.
-
Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R, Schaaf HS, Seddon JA, Furin J, Achar J, Radke K, Sachs T, Abubakirov A, Ahmed S, Akkerman OW, Al Ani NA, Amanullah F, Ahmad N, Anderson LF, Asfaw M, Bango F, Bauer T, Becerra M, Boeree M, Brinkmann F, Brown R, Brust J, Campbell JR, Carvalho AC, Carvalho I, Cegielski JP, Centis R, Chan ED, Chauhan S, Chiang SS, Chan PC, D'Ambrosio L, Dalcolmo M, Daneilyan N, de Vries G, Draper HR, Fairlie L, Francis JR, Franke M, Gegia M, Restrepo CG, Guenther A, Gureva T, Haecker B, Harausz E, Hewison C, Hicks RM, Huerga H, Hughes J, Isaakidis P, Kadri SM, Khan MA, Kotrikadze T, Kuksa L, Lachenal N, Lange C, Lecca L, Lopez-Varela E, Lucena S, Mariandyshev A, Mattoo S, Mendez-Echevarria A, Migliori GB, Mitnick C, Mohr-Holland E, Mulanda W, Murzabakova T, Myrzalieve B, Ndjeka N, Niemann S, Ozere I, Padayatchi N, Parmar M, Parpieva N, Manzur-Ul-Alam M, Rybak N, Sachdeva KS, Salmon K, Santiago-Garcia B, Schaub D, Shah I, Shah S, Shah V, Sharma S, Shim TS, Shin S, Sinha A, Skrahina A, Solanki H, Solans BP, Soriano-Arandes A, Toktogonova A, van der Werf T, Velásquez GE, Williams B, Yim JJ, Savic R, Hesseling A. Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis. Lancet Child Adolesc Health. 2025 02; 9(2):100-111.
-
Wynn EA, Dide-Agossou C, Al Mubarak R, Rossmassler K, Ektnitphong V, Bauman AA, Massoudi LM, Voskuil MI, Robertson GT, Moore CM, Walter ND. Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during prolonged treatment of mice. Antimicrob Agents Chemother. 2025 02 13; 69(2):e0131024.
-
Lienhardt C, Dooley KE, Nahid P, Wells C, Ryckman TS, Kendall EA, Davies G, Brigden G, Churchyard G, Cirillo DM, Di Meco E, Gopinath R, Mitnick C, Scott C, Amanullah F, Bansbach C, Boeree M, Campbell M, Conradie F, Crook A, Daley CL, Dheda K, Diacon A, Gebhard A, Hanna D, Heinrich N, Hesseling A, Holtzman D, Jachym M, Kim P, Lange C, McKenna L, Meintjes G, Ndjeka N, Nhung NV, Nyang'wa BT, Paton NI, Rao R, Rich M, Savic R, Schoeman I, Makokotlela BS, Spigelman M, Sun E, Svensson E, Tisile P, Varaine F, Vernon A, Diul MY, Kasaeva T, Zignol M, Gegia M, Mirzayev F, Schumacher SG. Target regimen profiles for tuberculosis treatment. Bull World Health Organ. 2024 Aug 01; 102(8):600-607.
-
Semitala FC, Kadota JL, Musinguzi A, Welishe F, Nakitende A, Akello L, Kunihira Tinka L, Nakimuli J, Ritar Kasidi J, Bishop O, Nakasendwa S, Baik Y, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PP, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial. PLoS Med. 2024 Feb; 21(2):e1004356.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|